Abstract

Context: In March 2003, the French Ministry of Health implemented a program on preparedness and response to a biological attack using smallpox as weapon. This program included the establishment of a preoutbreak national team that could be revaccinated against smallpox.

Objective: To identify demographic and clinical factors associated with vaccination success defined as the presence of a pustule at the inoculation site at day 8 (days 7–9), with an undiluted vaccinia virus derived from a Lister strain among preimmunized volunteers.

Volunteers and Methods: From March 2003 to November 2006, we have studied prospectively 226 eligible volunteers. Demographic data were recorded for each volunteer (age, sex, number of previously smallpox vaccinations and date of the last vaccination). Smallpox vaccine adverse reactions were diagnosed on the basis of clinical examination performed at days 0, 7, 14, 21 and 28 after revaccination.

Results: A total of 226 volunteers (sex ratio H/F = 2.7) were revaccinated. Median age was 45 years (range: 27–63 yrs). All volunteers completed follow-up. Median number of vaccinations before revaccination was 2 (range: 1–8). The median delay between time of the study and the last vaccination was 29 years (range; 18–60 yrs). Sixty-one volunteers (27%) experienced one (n = 40) or more (n = 21) minor side effects during the 2–14 days after revaccination. Successful vaccination was noted in 216/226 volunteers (95.6%) at day 8 and the median of the pustule diameter was 5 mm (range: 1–20 mm). Size of the pustule at day 8 was correlated with age (p = 0.03) and with the presence of axillary adenopathy after revaccination (p = 0.007). Sex, number of prior vaccinations, delay between the last vaccination and revaccination, and local or systemic side effects with the exception of axillary adenopathy, were not correlated with the size of the pustule at day 8.

Conclusions: Previously vaccinated volunteers can be successfully revaccinated with the Lister strain.
new case of smallpox would have to be the result of human accidental or deliberate release, could be associated to a major epidemic.

In March 2003, the French Ministry of Health implemented a program on preparedness and response to a biological attack using smallpox as weapon [7]. This program included the establishment of a proactive national team that could be revaccinated against smallpox and can be called upon to investigate and manage initial suspected or confirmed cases of smallpox in France. People, who were selected to this team, were eligible volunteers, had received at least one dose of smallpox vaccine in the past and have no contraindication to a revaccination. This program used the Lister strain (Pourquier® vaccine) which received French Health Products Safety Agency (AFSSAPS) licensure for this exclusive purpose.

The objective of this study was to identify demographic and clinical factors associated with vaccination success, defined as the presence of a pustule at the inoculation site eight days post vaccination and measured by the size of the pustule among 226 eligible preimmunized volunteers.

**Methods**

From March 2003 to November 2006, we have studied prospectively 226 eligible volunteers selected for the French national team against smallpox. They have received at least one dose of smallpox vaccine in the past, without major side effects, and have evidence of vaccine “take” as evidenced by the presence of a scar resulting from previous smallpox vaccination or notification on a notebook vaccination. Reimmunization for this team was performed with the Lister strain (Pourquier® vaccine). Screening to identify and exclude subjects with contraindications for them or household close contacts to smallpox immunization was performed (table 1). An HIV test was performed two weeks before vaccination. A urine pregnancy test on the day scheduled for vaccination was also performed for women of childbearing age. Written informed consent was obtained from all volunteers. French Health Products Safety Agency (AFSSAPS) approved this study.

There is currently two licensed smallpox vaccine in France using the Lister strain. There are approximately 72 millions doses of vaccine potentially available. The vaccine used (Pourquier® vaccine) contains live unattenuated vaccinia virus derived from the Lister strain which produces cross immunity against variola major and minor. The titer of vaccinia virus was $10^{7.7}$ pfu/mL. This lyophilized vaccine, product prepared from calf lymph, was reconstituted by adding sterile diluent to the powder and administered into the dermis by using the multiple-puncture technique with a presterilized bifurcated needle (10–15 punctures in an area of about 5 mm in diameter as recommended for revaccination over the insertion of the left deltoid muscle). The same physician performed all the vaccinations to exclude technical problems associated with the vaccination procedure. The vaccination site was covered with gauze in combination with a semipermeable membrane. Dressings were changed and the vaccination sites were assessed every seven days (d0–d28) until the lesions dried and an eschar formed. Following revaccination, vaccination success was measured by the development of a pustule at the inoculation site 7 to 9 days post vaccination.

Demographic data were recorded for each volunteer (age, sex, number of previously smallpox vaccinations and date of the last vaccination). There were no restrictions on work activities following revaccination. Smallpox vaccine adverse reactions were diagnosed on the basis of clinical examination performed at days 0, 7, 14, 21 and 28 after revaccination. Volunteers were also questioned at each follow-up visit for the presence of any vaccine-related adverse events such as local and systemic symptoms for at least 4 weeks after revaccination. Fever was defined as temperature ≥37.8°C.

The quantitative variables (i.e.: age, size of the pustule, delay between the vaccination and the revaccination) are not normally distributed. By consequence, the non parametric tests using exact calculation rather than asymptotic ones have been applied by using StatXact® software version 6 (Cytel Studio). Without any certainty regarding the hypothesis direction of the relation, all tests have been interpreted based on a two-tails p-value. The α risk has been chosen at 5%. The Bonferroni correction has been taken into account according to the number of tests done. The quantitative variables have been crossed by using the Mann-Whitney exact test. The Spearman rank correlation test has been used to test the correlation between quantitative variables.

**Results**

A total of 226 volunteers (sex ration H/F = 2.70) were revaccinated and included in this study (table 2). Median age of the cohort was 45 years (range: 27–63 years). All volunteers completed follow-up. All volunteers have been vaccinated against smallpox for the first time before one year old. Median number of vaccinations before revaccination was 2 (range: 1–8). Among volunteers, 45 (19.9%) received only one vaccination in the past.

| Table 1. Contraindications against vaccination for volunteers and household contacts (7). |
| --- |
| • History or presence of eczema or atopic dermatitis |
| • Other active acute, chronic or exfoliative skin conditions that disrupt the epidermis |
| • Conditions associated with immunosuppression (cancer, HIV, chemotherapy, radiotherapy, transplantation, autoimmune conditions, immunosuppressive medications..) |
| • Pregnancy, desire to become pregnant in the month following the revaccination or breastfeeding |
| • Having children <1 year |
| • Allergy to any component of the vaccine (polymyxin B, streptomycin, tetracycline or neomycin) |
| • Neurological disease |
| • Taking ocular steroid medication |
| • Heart disease |
| • Fever within 8 days before revaccination |

[doc10.1371/journal.pone.0004087.t001]
Discussion

The data of this study shows that volunteers previously immunized with smallpox vaccine are successfully revaccinated with an undiluted Lister strain.

Successful vaccination was noted in 216 of the 226 volunteers (95.6%). This result is in accordance with other studies which used an undiluted Lister strain [8,9]. Size of the pustule was significantly correlated with age and presence of axillary adenopathy after revaccination. As reported in another study, sex, number of prior immunizations and delay between the last vaccination and revaccination were not correlated with the size of the pustule at day 8 [10].

It has been usually reported that compared with vaccinia-naive subjects, prevaccinated patients had significantly smaller pustule lesion [11]. The fact that a larger size of the pustule was statistically correlated in our study with a greater age, suggests that some older prevaccinated volunteers are similar to vaccinia-naive individuals who do not have any immunity to smallpox. This can be due to loss of immune function with aging. However, this loss of immune function, is not correlated with number of prior immunizations and delay between the last vaccination and revaccination: both CD4+ and CD8+ cells specific for vaccinia virus have been found to persist for up to 75 years after the last immunization [12–14]. Moreover, persistence of humoral immunity to smallpox has been reported in patients up to 60 years after the last immunization [15].

In the literature, local lymphadenopathy is reported in 7 to 88% of cases [16]. But usually, and whatever the vaccine used, it has been reported that more naive subjects presented regional lymphadenopathy than non-naive subjects [17,18]. This could be the fact that vaccinia-naive volunteers shed virus from the vaccination site 2 to 6 days longer and had significantly higher peak mean viral titers when compared with prevaccinated volunteers [8,11].

It has been also reported that the 1:5 and 1:10 dilutions of smallpox vaccine in adults who had not been previously immunized, were associated with a smaller incidence of adenopathy than those reported in naive subjects given undiluted vaccine [19,20]. This is in accordance with our findings, suggesting that volunteers who have a larger pustule due to an increased local inflammation have an increase incidence of regional lymphadenopathy.

In our study, only 61 patients (27%) experienced at least one minor side effect during the 2–14 days after revaccination with the Lister strain. These side effects included only moderate local and/or systemic adverse events. No serious adverse effect, such as postvaccinal encephalitis, progressive vaccinia, eczema vaccinatum, generalized vaccinia, inadvertent inoculation, cardiac complication or death was notified in the volunteers and their household close contacts [21–25]. Local and systemic symptoms are quite common with this live viral vaccine, consistent with the presence of an acute viral illness. However, with the exception of fever, all the symptoms observed in our study were less frequent than those reported in vaccinia naive volunteers vaccinated with a lyophilized form (Dryvax, Wyeth Laboratories, Marietta, Pa.) and a frozen preparation (Aventis Pasteur, Swift-water, Pa.), live-virus vaccines, both derived from the New York City Board of Health vaccinia strain, even at diluted doses [17,19,20,26]. However, frequency of

Table 2. Characteristics of the volunteers before revaccination.

| Characteristics                  | Results          |
|----------------------------------|------------------|
| Number of volunteers             | 226              |
| Sex ratio (M/F)                  | 2.7 (165/61)     |
| Median age (range) yr            | 45 (27–63)       |
| Median number of prior vaccination (range) | 2 (1–8) |
| Median delay between the last vaccination yr (range) | 29 (18–60) |

The median delay between time of the study and the last vaccination was 29 years (range: 18–60 years).

Among the 226 volunteers, 61 (27%) experienced one (n = 40) or more (n = 21) minor side effects during the 2–14 days after revaccination. No side effect was notified and no adverse event was reported in their household close contacts. Moreover, no cardiac complication following revaccination was reported in this study. Local symptoms were: local pruritis (n = 17) (8%), axillary lymphadenopathy (n = 7) (3%), and large vaccination reaction (robust take) >7.5 cm in diameter (n = 2) (1%), and systemic symptoms were: fever >37.8°C (n = 27) (12%), fatigue (n = 14) (6%), headache (n = 6) (3%), myalgia (n = 6) (3%), nausea (n = 2) (1%), diarrhea (n = 2) (1%) and cough (n = 2) (1%) (Table 3).

Successful vaccination was noted in 216/226 volunteers (95.6%) at day 8 (days 7–9). Median of the pustule diameter in these 216 volunteers, at day 8 after revaccination was 5 mm (range: 1–22 mm): median age was 45.5 years (range: 27–63 years) and median delay between time of the study and the last vaccination was 29 years (range: 18–60 years). Among volunteers, 10 did not develop any clinical take (pustule diameter = 0) at the vaccination site (median age was 41 years (range: 33–49 years) and median delay between time of the study and the last vaccination was 33.5 years (range: 20–45 years). We did not find any difference between these two groups of volunteers with or without pustule.

A larger size of the pustule at day 8 was statistically correlated with a greater age (p = 0.03) and with the presence of axillary adenopathy after revaccination (p = 0.007). Sex, number of prior vaccinations, delay between the last vaccination and revaccination, and local or systemic side effects with the exception of axillary adenopathy, were not associated with the size of the pustule at day 8.

Table 3. Local and systemic symptoms among the 226 volunteers after the revaccination*.

| Adverse events                  | n (%)       |
|---------------------------------|-------------|
| fever >37.8°C                   | 27 (12)     |
| Fatigue                         | 14 (6)      |
| local pruritis                  | 17 (8)      |
| axillary lymphadenopathy        | 7 (3)       |
| headache                        | 6 (3)       |
| myalgia                         | 6 (3)       |
| nausea                          | 2 (1)       |
| diarrhea                        | 2 (1)       |
| cough                           | 2 (1)       |
| large vaccination reaction (diameter >7.5 cm)** | 2 (1) |

*61 volunteers (27%) experienced one (n = 40) or more (n = 21) side effects.

**ref (30).

doi:10.1371/journal.pone.0004087.t002

The relationship between age and the presence of axillary adenopathy has been reported in patients up to 60 years after immunization [12–14]. Moreover, persistence of humoral immunity to smallpox has been reported in patients up to 60 years after the last immunization [15].

In our study, only 61 patients (27%) experienced at least one minor side effect during the 2–14 days after revaccination with the Lister strain. These side effects included only moderate local and/or systemic adverse events. No serious adverse effect, such as postvaccinal encephalitis, progressive vaccinia, eczema vaccinatum, generalized vaccinia, inadvertent inoculation, cardiac complication or death was notified in the volunteers and their household close contacts [21–25]. Local and systemic symptoms are quite common with this live viral vaccine, consistent with the presence of an acute viral illness. However, with the exception of fever, all the symptoms observed in our study were less frequent than those reported in vaccinia naive volunteers vaccinated with a lyophilized form (Dryvax, Wyeth Laboratories, Marietta, Pa.) and a frozen preparation (Aventis Pasteur, Swift-water, Pa.), live-virus vaccines, both derived from the New York City Board of Health vaccinia strain, even at diluted doses [17,19,20,26]. However, frequency of
signs and the quantify of viral shedding [8].

This hypothesis is supported by the differences between previously vaccinated subjects and vaccinia-naïve subjects in local and systemic symptoms and signs and the quantity of viral shedding [8].

Previously vaccinated volunteers can be successfully revaccinated with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet 365: 988–909.

Author Contributions

Conceived and designed the experiments: PB GB JMC DG. Performed the experiments: PB FG IF BC BLV JMC DG. Analyzed the data: PB FG IF BC DG. Contributed reagents/materials/analysis tools: PB BC BLV BA DG. Wrote the paper: PB DG.

References

1. Bossi P, Garin D, Guihot A, Gay F, Crance JM, et al. (2006) Bioterrorism: management of major biological agents. Cell Mol Life Sci 63: 2196–212.

2. Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, et al. (1999) Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281: 2127–37.

3. Brennan J. Henderson D (2002) Diagnoses and management of smallpox. N Engl J Med 346: 1300–8.

4. Bartlett J, Borio L, Radonovich L, Mair JS, O’Toole T, et al. (2003) Smallpox vaccination in 2003: key information for clinicians. Clin Infect Dis 36: 803–902.

5. World Health Organization (1980) The global eradication of smallpox: final report of the global commission for the certification of smallpox eradication. Geneva, Switzerland: World Health Organization.

6. Levy-Brühl D, Guérin N (2001) The use of smallpox virus as a biological weapon: the vaccination situation in France. Euro Surveill 6: 171–8.

7. Plan national de réponse à une menace de variole (actualisation 2006) : http://www.sante.gouv.fr/htm/dossiers/urbc/urbc/menace_b/plan_variole_2006.pdf.

8. Kim SH, Yeo SG, Jang HC, Park WB, Lee CS, et al. (2005) Clinical responses to smallpox vaccine in vaccinia-naive and previously vaccinated populations: undiluted and diluted Lancy-Vaxina vaccine in a single-blind, randomized, prospective trial. J Infect Dis 192: 1066–70.

9. Ory N, Forman M, Marcos H, Lustig S, Paran E, et al. (2004) Clinical and immune responses after revaccination of Israeli adults with the Lister strain of vaccinia virus. J Infect Dis 190: 1295–302.

10. Combadiere B, Boissounas A, Carcelain G, Lefranc E, Samri A, et al. (2004) Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med 199: 1365–93.

11. Frey SE, Newman FK, Yan L, Lottenbach KR, Belche RB (2003) Response to smallpox vaccine in persons immunized in the distant past. JAMA 289: 9295–9.

12. Hammarlund E, Lewis MW, Carter SV, Amanna I, Hansen SG, et al. (2005) Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med 11: 1005–11.

13. Ennis FA, Cruz J, Demkowicz WE Jr, Rothman AL, McClain DJ (2002) Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-gamma-producing T cell memory after smallpox vaccination. J Infect Dis 185: 1657–9.

14. Demkowicz WE Jr, Littaua RA, Wang J, Ennis FA (1996) Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol 70: 2627–31.

15. Kim SH, Yeo SG, Park KH, Bang JW, Kim HB, et al. (2007) The persistence of immunological responses to undiluted and diluted smallpox vaccine with vaccinia virus of Lister strain. Vaccine 24: 510–5.

16. Metzger W, Mordmueller BG (2007) Vaccines for preventing smallpox. Cochrane Database Syst Rev Jul 18 (3): CD004913.

17. Greenberg RN, Kennedy JS, Clanton DJ, Plummer EA, Hague L, et al. (2005) Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet 365: 988–909.

18. Huich SM, Chou SY, Shou GG, Hung MN, Chou WH, et al. (2006) Clinical and immunological responses to undiluted and diluted smallpox vaccine with vaccinia virus of Lister strain. Vaccine 24: 510–5.

19. Frey SE, Couch RB, Tacket CO, Treanor J, Wolff M, et al. (2002) Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 346: 1265–74.

20. Frey SE, Newman FK, Cruz J, Shelton WB, Temnant JM, et al. (2002) Dose-related effects of smallpox vaccine. N Engl J Med 346: 1273–80.

21. Casey CG, Iskander JK, Roper MH, Mast EE, Werx J, et al. (2003) Adverse events associated with smallpox vaccination in the United States, January–October 2003. JAMA 294: 2734–43.

22. Seijar J, Labutta RJ, Chapman LE, Grabenstein JD, Iskander J, et al. (2005) Neurologic adverse events associated with smallpox vaccination in the United States, 2002–2004. JAMA 294: 2744–50.

23. Halsey JS, Rudie JR, Atwood JE, Gardner P, Shope R, et al. (2003) Mysoparcitalinitis following smallpox vaccination among vaccinia-naïve US military personnel. JAMA 299: 3283–9.

24. Vellozzi C, Lane JM, Averhoff F, Maurer T, Norton S, et al. (2005) Generalized vaccinia, progressive vaccinia, and eczema vaccinatum are rare following smallpox (vaccinia) vaccination: United States surveillance. Clin Infect Dis 2005 41: 689–97.

25. Casey C, Vellozzi C, Mostow GT, Chapman LE, McCaulley M, et al. (2006) Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR Recomm Rep 55(RR-1): 1–16.

26. Talbot TR, Stapleton JT, Brady RC, Winokur PL, Bernstein D, et al. (2004) Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial. JAMA 292: 1265–74.

27. Artenstein AW, Johnson C, Marbury TC, Morrison D, Blum PS, et al. (2005) A novel, cell culture-derived smallpox vaccine in vaccinia-naïve adults. Vaccine 23: 1301–9.

28. Ferrier-Rembert A, Drillien R, Meignier B, Garin D, Crance JM (2007) Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate. Vaccine 25: 2896–7.

29. Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, et al. (2007) Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Vaccine 25: 1513–25.

30. Graham PL, LalRusa P, Kohl K (2007) The Brighton Collaboration Vaccinia Virus Adverse Event Working Group. Robust take following exposure to vaccinia virus: Case definition and guidelines of data collection, analysis, and presentation of immunization safety data. Vaccine 25: 5763–5770.